JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Kura Oncology Inc

Cerrado

SectorSanidad

8.88 1.6

Resumen

Variación precio

24h

Actual

Mínimo

8.75

Máximo

8.93

Métricas clave

By Trading Economics

Ingresos

-6.9M

-81M

Ventas

-3.4M

17M

Margen de beneficios

-467.23

Empleados

260

EBITDA

-12M

-86M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+221.49% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

50M

805M

Apertura anterior

7.28

Cierre anterior

8.88

Noticias sobre sentimiento de mercado

By Acuity

58%

42%

304 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 abr 2026, 23:08 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 23:07 UTC

Ganancias

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:20 UTC

Ganancias

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 abr 2026, 23:27 UTC

Charlas de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 abr 2026, 23:22 UTC

Ganancias

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 abr 2026, 23:20 UTC

Charlas de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 abr 2026, 22:52 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:33 UTC

Ganancias

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 abr 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 abr 2026, 22:05 UTC

Ganancias

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 21:57 UTC

Ganancias

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 abr 2026, 21:55 UTC

Ganancias

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 abr 2026, 21:53 UTC

Ganancias

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

221.49% repunte

Estimación a 12 Meses

Media 28.13 USD  221.49%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

304 / 347 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat